In another liver disease, MASLD, overexpression of hepatic ActA was found to counteract MASLD by reducing liver steatosis, systemic fat accumulation, and inflammation, while improving insulin sensitivity (Liu, H. et al., 2023b). Here, ACTA1 is linked to metabolic dysfunction-associated steatotic liver disease.